Premium
Heterogeneity in the Allosteric Interaction Between the γ‐Aminobutyric Acid (GABA) Binding Site and Three Different Benzodiazepine Binding Sites of the GABA A /Benzodiazepine Receptor Complex in the Rat Nervous System
Author(s) -
Ruano Diego,
Vizuete Marisa,
Cano Josefina,
Machado Alberto,
Vitorica Javier
Publication year - 1992
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.1992.tb09747.x
Subject(s) - zolpidem , allosteric regulation , gabaa receptor , flunitrazepam , receptor , benzodiazepine , aminobutyric acid , chemistry , gaba receptor , cerebellum , agonist , binding site , pharmacology , cerebral cortex , neuroscience , biochemistry , biology , insomnia
In the present communication we have investigated the allosteric coupling between the γ‐aminobutyric acid A (GABA A ) receptor and the pharmacologically different benzodiazepine (BZD) receptor subtypes in membranes from various rat nervous system regions. Two types of BZD receptors (type I and type II) have been classically defined using CL 218.872. However, using zolpidem, three different BZD receptors have been identified by binding displacement experiments in membranes. These BZD receptor subtypes displayed high, low, and very low affinity for zolpidem. The distribution of the high‐ and low‐affinity binding sites for zolpidem was similar to that of type I and type II subtypes in cerebellum, prefrontal cortex, and adult cerebral cortex. On the other hand, the very‐low‐affinity binding site was localized in relative high proportion in spinal cord, hippocampus, and newborn cerebral cortex and, to a minor extent, in superior colliculus. The allosteric coupling between the GABA A receptor and the BZD receptor subtypes was different. The high‐ and low‐affinity binding sites for zolpidem seemed to have a similar high degree of coupling, except in spinal cord. On the other hand, the very‐low‐affinity binding site for zolpidem displayed a low degree of coupling with the GABA A receptor. These results seem to indicate that the different efficacy of GABA in enhancing the [ 3 H]flunitrazepam binding could be due to the different BZD receptor subtypes present in the GABA A /BZD receptor complex and, moreover, led us to speculate that the low GABA efficacy found in membranes from spinal cord, hippocampus, and newborn cerebral cortex might be due to the presence in relatively high proportion of the very‐low‐affinity binding site for zolpidem.